In hepatocellular carcinoma, the FASN inhibitor TVB‐3664 demonstrated effective antitumor activity in combination with tyrosine kinase inhibitors commonly used in advanced hepatocellular carcinoma, such as sorafenib [42]. The gene discussed is FASN; the disease is hepatocellular carcinoma.